Antifungal Drug Therapeutic Monitoring: What are the Issues?

被引：10
作者：
Myers E. [1 ]
Dodds Ashley E. [2 ]
机构：
[1] Strong Memorial Hospital, 601 Elmwood Avenue Box 638, Rochester, 14642, NY
[2] Strong Memorial Hospital, 601 Elmwood Avenue, Rochester, 14642, NY
来源：
Current Clinical Microbiology Reports | 2015年 / 2卷 / 2期
关键词：
Antifungal; Flucytosine; Isavuconazole; Itraconazole; Posaconazole; Therapeutic drug monitoring; Voriconazole;
D O I：
10.1007/s40588-015-0019-x
中图分类号：
学科分类号：
摘要：
Therapeutic drug monitoring (TDM), an established practice for many antimicrobials, has recently seen increasing utilization in the management of patients receiving antifungal agents. There is a growing body of literature supporting the use of TDM for itraconazole, voriconazole, posaconazole, and flucytosine. In addition, clinical practice guidelines have been recently published that give recommendations on the appropriate use of TDM for antifungal agents. However, there are still uncertainties regarding the optimal use of antifungal TDM in clinical practice. We conducted a review of recent literature in order to describe the clinical situations and specific antifungal agents for which TDM is ideal and summarize key information about the pharmacokinetics, pharmacodynamics, drug toxicities, TDM concentration targets, and dose adjustment algorithms for antifungals in which routine TDM is performed. © 2015, Springer International Publishing AG.
引用
收藏
页码：55 / 66
页数：11
相关论文
共 97 条
  • [1] Ashbee H.R., Et al., Therapeutic drug monitoring (TDM) of antifungal agents: Guidelines from the British Society for Medical Mycology, J Antimicrob Chemother, 69, 5, pp. 1162-1176, (2014)
  • [2] Andes D., Pascual A., Marchetti O., Antifungal therapeutic drug monitoring: established and emerging indications, Antimicrob Agents Chemother, 53, 1, pp. 24-34, (2009)
  • [3] Hope W.W., Et al., Therapeutic drug monitoring for triazoles, Curr Opin Infect Dis, 21, 6, pp. 580-586, (2008)
  • [4] Smith J., Andes D., Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations, Ther Drug Monit, 30, 2, pp. 167-172, (2008)
  • [5] Howard S.J., Et al., Posaconazole: the case for therapeutic drug monitoring, Ther Drug Monit, 34, 1, pp. 72-76, (2012)
  • [6] Hamada Y., Et al., Practice guidelines for therapeutic drug monitoring of voriconazole: A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring, J Infect Chemother, 19, 3, pp. 381-392, (2013)
  • [7] Bruggemann R.J., Et al., Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents, Clin Infect Dis, 48, 10, pp. 1441-1458, (2009)
  • [8] Kim H., Et al., Use of high-performance liquid chromatographic and microbiological analyses for evaluating the presence or absence of active metabolites of the antifungal posaconazole in human plasma, J Chromatogr A, 987, 1-2, pp. 243-248, (2003)
  • [9] Law D., Moore C.B., Denning D.W., Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards, Antimicrob Agents Chemother, 38, 7, pp. 1561-1566, (1994)
  • [10] Muller C., Et al., HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases, Mycoses, 49, pp. 17-22, (2006)
12345678910